A Financial Times Service
China Confidential - Premium Investment Insight

Consumer China

17 June 2010

Profits have come under pressure at the drug retailer from price ceilings on products under China's essential drug list.


We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on this website. However, if you would like to, you can change your cookie settings at any time. Find out more about our cookie policy.